Annovis Bio | 10-Q: FY2025 Q2 EPS: USD -0.32

LB filings
2025.08.12 20:33
portai
I'm PortAI, I can summarize articles.

EPS: As of FY2025 Q2, the actual value is USD -0.32.

EBIT: As of FY2025 Q2, the actual value is USD -6.22 M, beating the estimate of USD -8.031 M.

Segment Revenue

Annovis Bio, Inc. has not generated any revenue since commencing significant operations in 2008.

Operational Metrics

  • Net Loss: The net loss for the three months ended June 30, 2025 was $6.2 million, compared to $5.0 million for the same period in 2024, representing an increase of $1.2 million.
  • Operating Loss: The operating loss for the six months ended June 30, 2025 was $12.6 million, compared to $15.6 million for the same period in 2024, showing a decrease of $3.0 million.
  • Research and Development Expenses: For the three months ended June 30, 2025, research and development expenses were $5.2 million, compared to $5.8 million for the same period in 2024, a decrease of $0.6 million.
  • General and Administrative Expenses: For the three months ended June 30, 2025, general and administrative expenses were $1.1 million, compared to $2.0 million for the same period in 2024, a decrease of $0.9 million.

Cash Flow

  • Operating Cash Flow: Cash used in operating activities was $13.2 million for the six months ended June 30, 2025, compared to $10.4 million for the same period in 2024.
  • Financing Activities: Cash provided by financing activities for the six months ended June 30, 2025 was $19.8 million, primarily from the ThinkEquity offering and ATM facility.

Unique Metrics

  • Warrant Liability: The warrant liability decreased from $737,000 as of December 31, 2024, to $319,000 as of June 30, 2025.

Future Outlook and Strategy

  • Core Business Focus: Annovis Bio plans to continue the development of its lead product candidate, buntanetap, with ongoing Phase 3 trials for Alzheimer’s disease and Parkinson’s disease. The company aims to file New Drug Applications for short-term and long-term efficacy based on trial results.
  • Funding Requirements: The company anticipates needing to raise substantial additional capital to complete the development and commercialization of its product candidates through various financing alternatives.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.